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Histone deacetylase (HDAC) inhibitors are in clinical
development for several diseases, including cancers
and neurodegenerative disorders. HDACs 1 and 2 are
among the targets of these inhibitors and are part
of multisubunit protein complexes. HDAC inhibitors
(HDACis) block the activity of HDACs by chelating
a zinc molecule in their catalytic sites. It is not known
if the inhibitors have any additional functional effects
on the multisubunit HDAC complexes. Here, we find
that suberoylanilide hydroxamic acid (SAHA), the
first FDA-approved HDACi for cancer, causes the
dissociation of the PHD-finger-containing ING2 sub-
unit from the Sin3 deacetylase complex. Loss of
ING2 disrupts the in vivo binding of the Sin3 complex
to the p21 promoter, an important target gene for cell
growth inhibition by SAHA. Our findings reveal a
molecular mechanism by which HDAC inhibitors dis-
rupt deacetylase function.
INTRODUCTION
Histone deacetylases (HDACs) remove acetyl groups from
histones as well as nonhistone proteins. Histone hyperacetyla-
tion is generally correlated with gene expression, and HDACs
often work to repress gene expression. Inhibitors of HDACs
(HDACis) show promise as anticancer agents as well as in
therapies for neurodegenerative diseases (Khan and La
Thangue, 2008; Wiech et al., 2009). The hydroxamic acid
SAHA is currently used as a treatment for advanced and refrac-
tory cutaneous T cell lymphoma (CTCL) (Khan and La Thangue,
2008; Mann et al., 2007). A second HDACi, Istodax (also known
as romidepsin, depsipeptide, and FK228), has also recently been
approved for CTCL treatment (http://www.fda.gov/AboutFDA/
CentersOffices/CDER/ucm189466.htm). HDACis can inhibit
cancer progression through a number of mechanisms, including
inducing apoptosis, arresting cells in G1/S or G2/M, and causing
cells to differentiate (Frew et al., 2009; Marks and Xu, 2009;
Smith and Workman, 2009). One of the mechanisms by which
HDACis work is through modulation of gene expression by acet-
ylation of histones, to produce a transcriptional program that is
favorable for cell cycle arrest or apoptosis (Frew et al., 2009;Chemistry & Biology 17,Marks and Xu, 2009; Smith and Workman, 2009). Overall,
HDACis cause a small percentage of genes to be misregulated
transcriptionally, and, in this subset of genes, some are upregu-
lated, whereas some are downregulated (Smith, 2008; Van
Lint et al., 1996). In addition, HDACis mediate the acetylation
of many nonhistone proteins, although this also appears to be
a rather small subset of all possible acetylated proteins (Choudh-
ary et al., 2009; Spange et al., 2009).
There are four classes of HDACs. Classes I, II, and IV are zinc-
dependent hydrolases, whereas Class III HDACs are nicotin-
amide adenine dinucleotide (NAD+)-dependent enzymes called
sirtuins (Yang and Seto, 2008). There are 11 known zinc-depen-
dent HDACs (Class I: HDACs 1–3 and 8; Class II: HDACs 4–7, 9,
and 10; Class IV: HDAC 11) (Yang and Seto, 2008). Many
inhibitors being tested as anticancer agents affect several of
these enzymes. Crystal structures have been solved for a bacte-
rial Class I homolog and for human HDACs 7 and 8 in complex
with the hydroxamic acid inhibitors trichostatin A (TSA) and
SAHA (Finnin et al., 1999; Schuetz et al., 2008; Vannini et al.,
2004). These inhibitors work by chelating a zinc molecule in the
active site of the HDACs through their hydroxamic acid moieties
(Finnin et al., 1999; Schuetz et al., 2008; Vannini et al., 2004).
Because these molecules contain aliphatic chains that extend
out through the normal acetyl lysine-binding pockets in the
HDACs, they alsomay inhibit binding of the HDAC to their normal
acetyl lysine substrates (Finnin et al., 1999; Schuetz et al., 2008;
Vannini et al., 2004). Many inhibitors in clinical development
affect several HDACs; therefore, work has recently focused on
understanding which HDACs are needed to mediate the anti-
cancer effects of the inhibitors (Balasubramanian et al., 2009;
Witt et al., 2009). The goal is to obtain cancer cell growth-inhibit-
ing properties while maximizing the selectivity of the inhibitors.
Studies suggest that, in vivo, HDACs 1 and 2 play a role in medi-
ating cell growth arrest by these molecules (Glaser et al., 2003;
Haberland et al., 2009).
However, HDACs1 and 2 do not work alone; rather, they reside
in multisubunit chromatin modifying complexes, of which three
have been characterized: Mi-2/NuRD, which contains HDAC,
histone demethylase, and chromatin remodeling activities;
CoREST, which can repress neuronal-specific genes in non-
neuronal cells; and Sin3, which has been implicated in cell cycle
control (Wang et al., 2009; Yang and Seto, 2008). Residency in
these complexes is important for full activity and specificity of
these HDACs in the cell (Alland et al., 2002; Denslow and
Wade, 2007). However, it is not known if HDACis act directly on65–74, January 29, 2010 ª2010 Elsevier Ltd All rights reserved 65
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Figure 1. SAHA Alters the Biochemical Properties of the Sin3 Complex
(A andB) HDACassayswere performed on 3H acetylated core histoneswith (A) FL-BRMS1-purified complexes (top panel) or (B) FL-ING2-purified complexes (top
panel). DMSO and SAHA labels indicate that complexes were purified from 293T cells treated for 9 hr with these compounds. The SAHA (in vitro) label indicates
that complexes were purified from untreated cells and that SAHA was added directly to the deacetylation reaction. Error bars in (A) and (B) represent ± standard
deviation. Amounts of complex used in the assays were normalized to levels of (A) FL-BRMS1 (lower panel) or to levels of (B) FL-ING2 (lower panel).
(C) Western blot analysis of FLAG-tagged proteins bound to histone peptides.
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Deacetylase Inhibitors Disrupt the Sin3 Complexthese multisubunit complexes. The Sin3 complex is a 1.2 MDa
complex implicated in cell cycle control through its interactions
with the tumor suppressor protein Rb and can repress E2F-medi-
ated transcription to prevent progression to S phase (Lai et al.,
2001). TheSin3 complex is also implicated in controlling progres-
sion through the G2 phase of the cell cycle (David et al., 2003;
Pile et al., 2002). Therefore, this complex is among the potential
targets of HDACis that could mediate the growth arrest by these
molecules. We set out to determine if HDACis had any effects on
the multisubunit Sin3 complex, and if the complex was still intact
after the HDACs were bound to the inhibitors.
RESULTS
ING2-Purified Complexes Are Altered by HDACis
To determine if HDACis alter the properties of the Sin3 com-
plex, we purified the complex from 293T cells that stably
expressed tagged subunits. We used two different known66 Chemistry & Biology 17, 65–74, January 29, 2010 ª2010 Elseviersubunits of the Sin3 complex as baits for these purifications,
inhibitor of growth 2 (ING2), which binds to H3K4 that is di-
and trimethylated through its PHD finger, and breast cancer
metastasis suppressor 1 (BRMS1), which has an unknown
function in the complex (Doyon et al., 2006; Meehan et al.,
2004; Shi et al., 2006). The ING2 gene is deleted in some
head and neck carcinomas, whereas BRMS1 is important for
suppressing cancer metastasis, suggesting that their roles in
the Sin3 complex could be related to cell growth and cancer
progression (Seraj et al., 2000; Sironi et al., 2004). We per-
formed purifications from cells treated with the HDAC inhibitor
SAHA (7.5 mM) or DMSO and tested if there were differences
in the HDAC activities of the complexes. Sin3 complexes puri-
fied through the BRMS1 subunit from SAHA-treated cells still
had HDAC activity on acetylated core histones, suggesting
that the inhibitor was lost during the purification (Figure 1A).
This result is consistent with kinetic analyses of these compet-
itive inhibitors (Sekhavat et al., 2007). These complexes wereLtd All rights reserved
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Deacetylase Inhibitors Disrupt the Sin3 Complexstill sensitive to SAHA, however, because adding inhibitor
in vitro to the HDAC assay reduced catalytic activity (Figure 1A).
By contrast, complexes purified through ING2 from SAHA-
treated cells had reduced HDAC activity, similar to that
observed when SAHA was added directly to the HDAC assay
(Figure 1B). We wondered if this was due solely to a change
in catalytic activity, or if it also affected the ability of the com-
plex to bind directly to histones.
To ask if histone binding was disrupted, we tested the binding
of Sin3 complexes purified from SAHA/DMSO-treated cells to
histone peptides. The Sin3 complex preferentially binds to hypo-
acetylated histones through the RbAp46/48 subunits (Vermeulen
et al., 2004; Yoon et al., 2005). It can also be recruited to chro-
matin through the H3K4-di/trimethyl mark by ING1/2 (Pena
et al., 2008; Shi et al., 2006). Therefore, we tested the ability of
the complexes to bind unmodified and H3K4 trimethylated
peptides. We found that complexes purified through the ING2
subunit in the presence of SAHA were compromised in their
ability to bind to histone peptides (Figure 1C). By contrast,
complexes purified through BRMS1 retained the ability to bind
to histone peptides after SAHA treatment (Figure 1C). Thus,
Sin3 complexes purified through ING2 from cells treated with
SAHA lost HDAC activity and histone-binding ability, whereas
the BRMS1 purified complexes did not.
HDACis Cause ING2 to Dissociate from the Sin3
Complex
To elucidate the molecular basis for the altered properties of
ING2-purified Sin3 complexes from cells treated with SAHA,
we examined the composition of the complexes. Silver-stained
gels of the purified complexes revealed that ING2 purified
from SAHA-treated cells had reduced levels of other Sin3
complex subunits associated with it (Figure 2A). Multidimen-
sional protein identification technology (MudPIT) (Paoletti et al.,
2006) and western blot analysis confirmed that this loss included
reductions in HDAC1, Sin3a, SDS3, and other known subunits
(Figure 2B; see Table S1 available online). This effect was not
limited to SAHA, because other HDACis, including TSA and a
cyclic tetrapeptide, apicidin, also dissociated FLAG-ING2 from
Sin3 complex subunits; however, sodium butyrate and valproic
acid did not (Figures S1A and S1B). Therefore, specific deacety-
lase inhibitors can mediate the dissociation of ING2 from the
Sin3 deacetylase complex.
The tagged bait protein ING2 was overexpressed in these
initial experiments; therefore, we tested if the association of
endogenous ING2 with the Sin3 complex was changed after
SAHA treatment of 293T cells. We analyzed Sin3 complexes
purified through BRMS1 and an additional subunit, BRMS1-
LIKE (Nikolaev et al., 2004), by SDS-PAGE. BRMS1 purifications
from cells treated with SAHA for 9 hr showed reduced silver
staining of a band at 33 kDa, which is the predicted size of
ING2 (Figure 2C). Western blots and MudPIT analysis confirmed
a reduction of endogenous ING2, but not ING1, in the BRMS1
and BRMS1-LIKE purifications (Figures 2D and 2F; Table S2),
and this occurred as early as 3 hr postdrug treatment (Fig-
ure S1C). Total nuclear levels of ING2 and HDAC1 were not
changed by SAHA treatment (Figure 2E). Thus, the ING2 protein
was still intact in SAHA-treated cells, and SAHA was causing its
dissociation from the Sin3 complex.Chemistry & Biology 17,SAHAandotherHDACis havebeen shown toeffectively halt the
growth of many cell types, including breast cancer cells (Huang
and Pardee, 2000). Therefore, we wanted to know if the dissocia-
tion of ING2 also occurred in cancer cells. We treated MDA-MB-
231 breast carcinoma cells with DMSO or SAHA and performed
immunoprecipitations with antibodies to endogenous ING2 or
HDAC1. After treatment of these cells with SAHA, the amount of
ING2 that coprecipitated with HDAC1 was reduced (Figure 2G).
Conversely, the amount of HDAC1 coprecipitated with ING2
was also reduced (Figure 2G). Thus, ING2 and HDAC1 were
also dissociated after SAHA treatment of breast carcinoma cells,
suggesting that this effect is a consequenceofHDACi treatment in
diverse cell types.
Dissociation of ING2 Occurs through a Direct
Mechanism
HDACis cause an accumulation of acetylated proteins in the cell.
This hyperacetylation raised the possibility that a subunit of the
Sin3 complex became acetylated during SAHA treatment, which
could be responsible for ING2 dissociation. We tested if acety-
lated proteins were detected in the SAHA-treated purifications;
however, we did not detect acetylated lysines in any Sin3
complex component after SAHA treatment (Figures S2A and
S2B) This finding is consistent with a recently published study
on the acetylome (Choudhary et al., 2009) that did not find large
increases in the acetylation of Sin3 subunits after HDACi treat-
ment. Next, we asked if the dissociation between ING2 and the
Sin3 complex could occur in vitro. We treated 293T whole-cell
extract with a panel of HDACis and again observed the dissoci-
ation between ING2 and the Sin3 complex with SAHA, TSA, and
apicidin (Figures 3A and 3B; Figure S1D). The addition of Acetyl-
CoA in the presence of SAHA to the whole-cell extract did not
enhance the dissociation of ING2 (Figure S2C). Finally, we tested
if histone acetyltransferase (HAT) inhibitors could prevent ING2
dissociation from the Sin3 complex. However, we found that
SAHA and TSA still caused dissociation of ING2 from the
complex in a whole-cell extract in the presence of a HAT inhibitor
(Figure S2D). Together, the results suggest that acetylation is not
needed for ING2 dissociation to occur.
Because ING2 can tether the Sin3 complex to chromatin, we
wondered if chromatin binding by ING2’s PHD finger was neces-
sary for SAHA to mediate the dissociation. We expressed an
ING2 lacking its PHD finger in 293T cells. This deletion mutant
was previously shown to maintain association with the Sin3
complex (Shi et al., 2006). We found that ING2 lacking its PHD
finger still dissociated from the Sin3 complex, after cells were
treated with SAHA (Figure S2E). Consistent with this result, we
also found that TSA did not prevent recombinant ING2 from
binding to an H3K4 trimethylated peptide (Figure S2F). Together,
the data suggest that neither acetylation nor chromatin binding
by ING2 are necessary for HDACi-mediated dissociation from
the Sin3 complex.
To determine if ING2 dissociation from the Sin3 complexmight
be a direct consequence of the HDAC binding to the inhibitor, we
asked if the dissociation could occur with purified Sin3 complex.
To test this hypothesis, we immobilized the Sin3 complex purified
through the BRMS1 subunit to FLAG beads and incubated the
complexwith increasing amounts of TSA.We found that the addi-
tion of TSA to the purified complex resulted in dissociation of65–74, January 29, 2010 ª2010 Elsevier Ltd All rights reserved 67
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Figure 2. HDAC Inhibitors Dissociate ING2 from the Sin3 Complex
(A) Silver stain analysis of FL-ING2 complexes purified fromDMSO or SAHA-treated 293T cells (7.5 mMSAHA or an equal volume of DMSOwas added to the cells
for 9 hr).
(B) Western blot analysis of FL-ING2 immunoprecipitations from (A) in the presence of SAHA.
(C) Silver-stained gels of FL-BRMS1 complexes purified from DMSO- or SAHA-treated 293T cells (7.5 mM SAHA or an equal volume of DMSO was added to the
cells for 9 hr). The arrows indicate the locations of endogenous ING2 and FLAG-BRMS1.
(D) Western blots of FLAG-BRMS1 purifications from (C).
(E) Western blots of nuclear extracts from DMSO- or SAHA-treated 293T cells.
(F) Relative percent dNSAF (distributed normalized spectral abundance factor) of proteins in SAHA versus DMSOpurifications as determined byMudPIT analysis.
Error bars represent ±1 standard deviation.
(G) Western blots of immunoprecipitated proteins from MDA-MB-231 breast carcinoma cells treated with 7.5 mM SAHA or DMSO for 9 hr.
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Figure 3. ING2 Dissociates through a Direct Mechanism
(A) HDACis or control compounds were added to whole-cell extracts from FLAG-BRMS1-expressing 293T cells, purified with FLAG affinity beads, and then
probed by western blot for the indicated proteins.
(B) Quantification of (A).
(C) FL-BRMS1-purified complex was immobilized on FLAG beads and treated with TSA or control (ethanol) and then probed by western blot for indicated
proteins.
(D) Quantification of (C). Bars in (B) and (D) represent the average of three experiments expressed as percent band intensity of ING2 in SAHA- or TSA-treated
extract or complex compared to the intensity in the control treatment, normalized to intensity of Sin3a. Error bars represent ±1 standard deviation.
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Deacetylase Inhibitors Disrupt the Sin3 Complexendogenous ING2 (Figures 3C and 3D). This finding suggests that
the dissociation of ING2 could be mediated by a direct/physical
disruption that does not require additional factors in cell extracts
or living cells. Thus, it appears that binding of the small-molecule
inhibitors to the catalytic sites of the HDAC enzymes leads to
physical dissociation of ING2 from the Sin3 complex.
SAHA Disrupts Sin3 Complex Binding at p21 through
Dissociation of ING2
The Sin3 complex contains several proteins that can recruit or
retain it at chromatin. These include RbAp46/48, SAP30 and
SAP30-LIKE, Sin3, and ING1 and ING2 (Shi et al., 2006; Vermeu-
len et al., 2004; Viiri et al., 2009; Yoon et al., 2005). Therefore,
ING2 is one of the many subunits through which the Sin3
complex can be tethered to chromatin. Because HDACis were
effective at dissociating ING2 from the Sin3 complex, we hypoth-
esized that SAHA could cause changes in occupancy of the Sin3
complex at promoters where binding was dependent on ING2.
The cyclin-dependent kinase inhibitor p21 is a tumor suppressor
that is transcriptionally induced in response to HDACis (RichonChemistry & Biology 17,et al., 2000; Smith and Workman, 2009). Previous studies have
shown that the occupancies of HDAC1 and HDAC2 were
reduced at the p21 TATA after HDAC inhibitor treatment (Gui
et al., 2004; Lin et al., 2008). To test if this might be due to
ING2 dissociation, we performed chromatin immunoprecipation
(ChIP) in 293T cells. We found that binding of ING2 and the
Sin3 complex were enriched at the p21 TATA region compared
to intron 1 in control-treated cells (Figure 4A). SAHA treatment
for 10 hr caused a reduction in ING2, HDAC1, and SAP30
occupancies (Figure 4A), but did not affect the levels of H3K4
trimethylation (Figure 4B) or H3 occupancy (Figure 4C) at the
p21 TATA. These results are consistent with our biochemical
studies indicating that ING2 is dissociated from the Sin3
complex in the presence of SAHA.
Because the Sin3 complex can be recruited and tethered to
chromatin through multiple subunits, we tested if occupancy of
the Sin3 complex was dependent on ING2 at p21. To do this
experiment, we assessed the occupancy of the Sin3 complex
in ING2 knockdown cells and compared this to control cells
expressing noneffective shRNA. As expected, the occupancy65–74, January 29, 2010 ª2010 Elsevier Ltd All rights reserved 69
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Figure 4. ING2 Dissociation Causes the Loss of the Sin3 Complex from the p21 Promoter
(A–F) (A–C) ChIP was performed in 293T cells treated for 10 hr with DMSO (D) or SAHA (S). (D–F) ChIP was performed in ING2 shRNA knockdown or noneffective
control (cntrl) shRNA knockdown 293T cells. Bars in (A)–(F) show the average from a representative experiment with primers adjacent to the p21 TATA or in intron
1 of p21. As a control in (B) and (E), percent inputs were normalized to the amount of H3 immunoprecipitated for each treatment condition or cell line. Error bars
represent ±1 standard deviation of triplicate or quadruplicate real-time PCR reactions.
(G) Total nuclear extracts from the ING2 knockdown cells or GFP shRNA control cells were probed for the indicated proteins.
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Deacetylase Inhibitors Disrupt the Sin3 Complexof ING2 at the p21 TATA was reduced in ING2 knockdown cells
(Figure 4D). Interestingly, the level of H3K4 trimethylation at this
region was also reduced in the ING2 knockdown line (Figure 4E),
but occupancy of H3 was not altered (Figure 4F), suggesting that
ING2 binding could protect this region from demethylation. The
occupancies of HDAC1 and SAP30 were also reduced at p21
in the ING2 knockdown cells compared to the control cell line,
showing that they were dependent on ING2 (Figure 4D). Total
levels of HDAC1 were not changed in the ING2 knockdown cells;
however, SAP30 protein levels were reduced in the ING2 knock-
down line, but not in cells treated with SAHA (Figure 4G; data70 Chemistry & Biology 17, 65–74, January 29, 2010 ª2010 Elseviernot shown). Thus, SAHA treatment promotes the loss of the
Sin3 complex from the p21 promoter in vivo through the dissoci-
ation of the ING2 subunit (Figures 5A and 5B).
DISCUSSION
Previous studies showed that the catalytic activities of HDACs
are important for their association with other proteins (Hassig
et al., 1998; Matsuoka et al., 2007). Catalytically inactive mutants
of HDAC1 do not associate with RbAp48 or Sin3 (Hassig et al.,
1998). However, here, we find that SAHA, the first FDA-approvedLtd All rights reserved
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Figure 5. Models for Gene Activation after HDAC Inhibitor Treatment
(A) The Sin3 complex can be tethered to chromatin through interactions of Rbp1 or Sin3 subunits with transcription factors (gray ovals and rectangle) and through
SAP30/SAP30-LIKE and RbAp46/48 subunits. At these promoters, HDACis cause inactivation of the HDACs and dissociation of ING2 from the complex.
(B) ING2 is required for tethering the Sin3 complex at some promoters where H3K4 is di-/trimethylated. At these regions, HDACi treatment causes inactivation of
the HDACs as well as dissociation of the Sin3 complex from chromatin.
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Deacetylase Inhibitors Disrupt the Sin3 ComplexHDACi for cancer treatment, does not alter HDAC1 or HDAC2
interactions with the Sin3 complex, consistent with findings
from a previous study (Sekhavat et al., 2007). Instead, we find
that HDACis affect the association of a nonenzymatic subunit
important for chromatin targeting, ING2.
The inhibitor of growth family of proteins contains five known
members in humans. ING1 and ING2 reside in Sin3 deacetylase
complexes, whereas ING3, ING4, and ING5 are in HAT com-
plexes (Doyon et al., 2006). It is interesting that all of these
proteins are thought to bind the same methylated histone
mark, H3K4 that is di- or trimethylated. It is unclear what controls
which INGprotein will be bound to this epigeneticmark at a given
time, and, therefore, whether a HAT or HDAC complex will be
recruited.
ING family members are of potential therapeutic interest
(Unoki et al., 2009). ING2 is of interest because of its role in
modulating p53 activity (Menendez et al., 2009; Nagashima
et al., 2001). In addition, ING2 can recruit the repressive Sin3
complex to the cyclin D1 promoter after DNA damage (Shi
et al., 2006). Here, we find that ING2 is also functionally targeted
by HDACis, and that HDACis cause ING2’s dissociation from the
Sin3 HDAC1/2 complex. ING2 is likely required for Sin3 complex
occupancy at a specific subset of Sin3 target genes. Therefore,Chemistry & Biology 17,the dissociation of ING2 is one possible mechanism that contrib-
utes to gene expression alterations after HDAC inhibitor treat-
ment (Figure 5).
We have tested several possibilities to explain the mechanism
bywhich ING2 dissociates from the Sin3 complex.We found that
TSA can cause ING2 to dissociate from purified Sin3 complex
in vitro and does not require additional factors in the cell.
In addition, we also showed that the dissociation does not
require acetylation of specific proteins, nor does this dissocia-
tion involve the PHD finger of ING2 directly. We also showed
that not all inhibitors are effective at dissociating ING2, suggest-
ing that dissociation is not simply due to the inhibition of catalytic
activity of the HDACs. Interestingly, the inhibitors that do
mediate the dissociation (TSA, SAHA, and apicidin) are larger
and bulkier than those that do not (Na butyrate, valproic acid),
suggesting that the ability to dissociate ING2 may involve the
structure of the inhibitors themselves. All of these results
together suggest that ING2 dissociates through a direct effect
of the HDACs binding to the inhibitors in the context of the
complex.
Our studies leave open the possibility that a conformational
change occurs in the complex after inhibitor binding. Showing
this change will require further structural studies of the HDACs65–74, January 29, 2010 ª2010 Elsevier Ltd All rights reserved 71
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have only been carried out on isolated deacetylases in complex
with inhibitors (Finnin et al., 1999; Schuetz et al., 2008; Vannini
et al., 2004). Future studies will have to address several ques-
tions. First, it is unclear how the multisubunit complexes are
assembled. Second, it is not known if the HDACs undergo
structural changes when they are assembled in the complexes.
Third, it is also unclear if inhibitor binding alters HDAC conforma-
tion in the context of their complexes. Our results suggest that
the HDACs bind to the inhibitors, and that this causes a confor-
mational change in at least part of the Sin3 complex, which is
sufficient for dissociation of ING2. Because the Sin3 complex
largely stays intact and is active without ING2, this suggests
that ING2 is not needed for the integrity of the complex as awhole
or for catalytic activity. The data also suggest that ING2 resides
on an outer surface of the complex and support a main role for
ING2 in targeting the Sin3 complex to chromatin.
ING2 is considered a stable subunit of the Sin3 complex;
however, we show here that dynamic interactions can occur
between ING2 and the Sin3 complex, and that this association
can be perturbed by HDAC inhibitors. ING2 has the ability to
dynamically respond to several cellular signals, including phos-
phoinositides and DNA damage (Gozani et al., 2003; Shi et al.,
2006). The model proposed by Shi et al. (2006) suggests that
ING2 can recruit the Sin3 complex for immediate gene repres-
sion when needed. Our results suggest that HDACis cause the
physical release of the Sin3 complex from promoters through
dissociation of ING2. This may be an important step that allows
recruitment of other factors and gene activation. Overall, our
results implicate ING2 and the Sin3 complex in mediating the
cellular response to HDAC inhibitors.
Disrupting just the ING2/Sin3 complex interaction should
lead to a smaller subset of gene expression changes than
treatment with pan-HDACis. Our results raise the question of
whether modulating the ING2/Sin3 interaction may be sufficient
to have any anticancer growth effects. It will be interesting
to test if reduction of ING2 protein levels is sufficient for induc-
tion of p21 and other genes associated with SAHA-mediated
growth inhibition. If so, disrupting this interaction may be of
therapeutic value, either alone or in combination with other
chemotherapeutic agents. Together, our findings reveal that
the Sin3 complex is among the in vivo targets for HDACis and
describe a new mechanism by which HDACis can alter HDAC
function.
SIGNIFICANCE
HDACis, such as SAHA, are being tested as treatments for
cancers and neurodegenerative diseases. Despite the ther-
apeutic successes of thesemolecules, we are just beginning
to understand how they work. The recognized mode of
action for these drugs is via binding to their target enzymes,
HDACs, and catalytically inhibiting their activity. This inhibi-
tion, in turn, leads to changes in the expression of specific
genes and produces a gene expression program that is
overall favorable for cell cycle arrest, apoptosis, or differen-
tiation. Unexpectedly, our findings here show that HDACis
can also disrupt critical protein-protein interactions
between HDACs 1 and 2 and ING2, a protein responsible72 Chemistry & Biology 17, 65–74, January 29, 2010 ª2010 Elsevierfor recruitment of the Sin3/HDAC1/2 complex to chromatin.
Abrogation of this interaction disrupts the targeting of
the Sin3/HDAC complex to chromatin. Therefore, HDACis
disrupt HDAC function not only by inhibiting HDAC catalytic
activity, but also by disrupting HDAC complex subunit
composition and chromatin targeting. These findings reveal
that these small-molecule inhibitors exert their effects
through multiple molecular modes of action.
EXPERIMENTAL PROCEDURES
Cell Lines and Culture
293T cells stably expressing FLAG-tagged subunits of the Sin3 complex were
made by using the Flp-In system (Invitrogen). 293T FRT cells were a gift from
Drs. Joan and Ron Conaway. MDA-MB-231 cells were obtained from Amer-
ican Type Culture Collection. All cell lines were maintained in DMEM (GIBCO)
supplemented with 10% FBS, Pen/Strep, and Glutamax (GIBCO) in a humidi-
fied atmosphere at 37C. For experiments involving drug treatment, HDACis or
appropriate vehicles (ethanol or DMSO) were added directly to the culture
media, and cells were collected at the indicated times. TSA and SAHA were
purchased from Cayman Chemical or BioVision, Inc., and apicidin, valproic
acid, and sodium butyrate were purchased from Sigma.
Purifications
293T whole-cell extracts were made by using a high-salt extraction method
(Mahrour et al., 2008). Anti-FLAG M2 agarose resin was added overnight to
the soluble protein fraction with rotation according to manufacturer’s instruc-
tions (Sigma). Complexes were eluted with 33 FLAG peptide and then
analyzed or used for MudPIT analysis or in biochemical assays. In purifications
with drug treatment, HDACis were included at all steps of the purifications,
except the elution step.
HDAC Assays
HDAC assays were performed with purified HDAC complexes, essentially as
described (Meehan et al., 2004), except HeLa core histones acetylated by
yeast SAGA were used as a substrate, and reactions were incubated for 1 hr
at 37C. DMSO or SAHA (7.5 mM) were included in the HDAC assays where
indicated.
Peptide-Binding Assays
Biotinylated histone peptides were either purchased from Upstate Biotech-
nology or were a gift from Dr. Matthias Mann (Max-Planck Institute). Binding
reactions were performed in 150 mM NaCl in the presence of 0.1% Triton
X-100 as described (Shi et al., 2006). For each assay, the entire bound sample
was run on SDS-PAGE.
In Vitro Dissociation Experiments
HDACis and Garcinol (where indicated) were added to whole-cell extracts
from 293T cells stably expressing FLAG-BRMS1. FLAG resin beads were
added concurrently with the HDAC/HAT inhibitors. In experiments with
Acetyl-CoA, HDACis and Acetyl-CoA were added at the same time with
FLAG resin to whole-cell extracts from 293T cells stably expressing FLAG-
ING2. In both experiments, the immunoprecipitations were incubated at 4C
overnight with rotation. The next day, unbound protein was removed, and
beads were washed four times with Buffer A (10 mM HEPES [pH 7.5], 0.2%
Triton X-100, 300 mM NaCl, 10 mM KCl, and 1.5 mMMgCl2). For dissociation
with purified complex, FL-BRMS1 complex was purified from untreated
whole-cell extracts, immobilized on FLAG beads, and washed four times
with Buffer A. Beads were then incubated in Buffer B (10 mM HEPES
[pH 7.5], 0.05% Triton X-100, 150 mM NaCl, and 1.5 mM MgCl2) with ethanol
or TSA for 2 hr at 30C with rotation. Unbound protein was removed, and
beads were washed four times with Buffer A.
Plasmids
Full-length cDNAs encoding human BRMS1, BRMS1L, or ING2, or ING2
lacking amino acids 208–280 (ING2DPHD) were cloned into pcDNA5/FRTLtd All rights reserved
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ING2, ING2DPHD) or C-terminal (BRMS1L) FLAG tag. HuSH 29-mer shRNA
constructs against ING2 (cat# TG312145) or noneffective shRNA (cat#
TR30008) were purchased from Origene Technologies and stably expressed
in 293T cells.
Chromatin Immunoprecipitation
Chromatin immunoprecipitation (ChIP) was performed as described by
Upstate Biotechnology, Inc., except antibodies were first bound to preblocked
Protein A Sepharose (Sigma) or Protein G Sepharose (Amersham) in binding
buffer (5 mM Tris [pH 7.5], 250 mM NaCl, 1 mM EDTA, 0.05% NP-40). ChIPs
were performed at least three independent times.
Antibodies
Antibodies used for ChIP, western blot, and immunoprecipitations are as
follows: anti-acetyl H4 (Upstate, 06-866), HDAC1 (Abcam-Ab7028), ING2 anti-
body (a gift from Dr. Or Gozani [Stanford] or purchased from ProteinTech
Group, Inc.; cat# 11560-1-AP), H3 antibody (Abcam-Ab1791), H3K4 trimethyl
(Abcam-Ab8580), Sin3a (Abcam-Ab3479), Sap30 (Upstate-06-875), acety-
lated-lysine antibodies (Cell Signaling Technology, cat# 9681, cat# 9441),
FLAG-HRP (Sigma).
Real-Time PCR
PCR was performed with a BioRad iCycler machine with SYBR green. Cycling
conditions are as follows: 3 min at 95C, then 41 cycles of: 10 s at 95, 30 s at
55 or 60, and 30 s at 72, then followed by a melt curve. A standard curve of
input DNA was used to determine relative ChIP sample abundance. Each
sample was run in triplicate or quadruplicate. Primers adjacent to the p21
TATA or in intron 1 (negative control) were used for real-time PCR of ChIP
samples. Sequences of primers are as follows: +85p21TATA-F: 50-GATTCG
CCGAGGCACCGAGGCA-30, +218p21TATA-R: 50-GAACACGCATCCTCGCG
GACAC-30, p21-IN1-F: 50-GTGCCTGCCTAGATCCTAGTCCT-30, p21-IN1-R:
50-GGAGACACACTGGTATGTTTGAA-30.
Quantification of Signal Intensity on Western Blots
Western blots were developed with ECL-Plus (GE Healthcare) and then
scanned on a Typhoon 9400 imaging system. Image Quant V 5.2 was used
to quantify bands by the volume integration method. Background was normal-
ized by using a local average, and a volume report was generated. ING2 band
intensity was normalized to Sin3a band intensity per lane.
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